Saturday 17 October 2026
Export CNSP’s income statement to Excel — free account
CNS Pharmaceuticals, Inc.
CNSP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.1% and free cash flow grew 33.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.85
0.33
−6.37%
Follow CNSP
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | 3,285,000.00 | 1,132,200.00 | 622,800.00 | 61,500.00 | 18,330.00 | 57.60 | 4.93 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | 5,121,000.00 | 5,058,000.00 | 4,014,000.00 | 1,242,000.00 | 132,000.00 | 39,000.00 | 114.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 8 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | 0 | (7) | (4) | (9) | (14) | (15) | (19) | (15) | (16) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (7) | (4) | (9) | (14) | (15) | (19) | (15) | (16) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | (0.01) | (63,324.49) | (25,212.60) | (51,325.66) | (47,723.86) | (336,734.70) | (113,152.60) | (466.63) | (35.75) | |||||
| Cash flow | — | (0.20) | (7,164.00) | (17,767.50) | (36,590.00) | 0.00 | 0.00 | (70,700.00) | (534.79) | (31.18) | |||||
| Capex | — | 0.00 | 0.00 | (100.50) | (89.50) | 0.00 | 0.00 | (19.50) | (0.13) | (0.04) | |||||
| Free cash flow | — | (0.20) | (7,164.00) | (17,868.00) | (36,679.50) | 0.00 | 0.00 | (70,719.50) | (534.92) | (31.22) | |||||
| Book value | — | (0.11) | (5,493.00) | 38,005.50 | 69,740.00 | 0.00 | 0.00 | (22,160.50) | 193.02 | 10.21 | |||||
| Shares, m | — | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | (1) | (4) | (7) | (14) | (11) | (14) | (17) | (14) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | 0 | (1) | (4) | (7) | (14) | (11) | (14) | (17) | (14) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 0 | (1) | 8 | 14 | 5 | 8 | (5) | 6 | 4 | ||||
| Total debt | — | 0 | 0 | — | 0 | 0 | 0 | — | — | — | |||||
| Net debt | — | 0 | 0 | (7) | (14) | (5) | (10) | (1) | (6) | (7) | |||||
| Shareholders’ equity | — | 0 | (1) | 8 | 14 | 6 | 8 | (4) | 6 | 5 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (51.90) | (2,163.59) | (90.22) | (79.59) | (117.80) | (140.06) | (255.54) | (285.68) | (182.99) | ||||
| ROIC | — | 0.00 | 0.00 | (665.82) | 0.00 | (781.37) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | 72.19 | 2,432.35 | (109.96) | (87.78) | (144.15) | (213.68) | (1,018.76) | (1,703.39) | (296.30) | |||||
Negative figures in brackets.
Charts ten years each
CNS Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BOLT Bolt Biotherapeutics, Inc. | $8.2M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +38.87% (above 0%: growing) | 100.00% | (167,480.00%) | Compare |
| SNTI Senti Biosciences, Inc. | $8.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | Compare |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $8.1M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| XTLB XTL Biopharmaceuticals Ltd. | $8.1M | — (loss-making) | — | −39.32% (below 0%: shrinking) | n/m | +46.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KPTI Karyopharm Therapeutics Inc. | $8.0M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| CNSP CNS Pharmaceuticals, Inc. | $7.9M | — (loss-making) | — | — | n/m | +33.70% (above 0%: growing) | 0.00% | 0.00% | |
| APRE Aprea Therapeutics, Inc. | $7.8M | — (loss-making) | — (loss-making) | −98.40% (below 0%: shrinking) | n/m | −5.22% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SNGX Soligenix Inc. | $7.7M | — (loss-making) | — (loss-making) | −98.89% (below 0%: shrinking) | n/m | +37.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CURX Curanex Pharmaceuticals Inc | $7.6M | — (loss-making) | — | — | n/m | −272.32% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $8.0M | — | — | −98.54% | — | −6.35% | 96.75% | 0.00% |
CNS Pharmaceuticals, Inc. (CNSP) key facts
- CNS Pharmaceuticals, Inc. (CNSP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CNSP traded at $4.85, a market capitalization of $7.9 million.
- Return on equity was −296.3% and debt-to-equity 0.00.